GHAPPcast

Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
  • 0,0 (0)
  • MEDICINA
GHAPPcast

This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs). Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).

  1. HÁ 21 H

    KOL: What Are the Most Critical Updates in Cirrhosis Research That Clinicians Should Be Aware Of?

    Cirrhosis is often considered an irreversible liver disease, but is there a chance for early-stage reversal? In this episode, Janet Gripshover, CRNP, Nurse Manager for the Cedars-Sinai Liver Transplant Program, dives deep into the latest advancements in cirrhosis treatment, liver transplant eligibility, and the evolving landscape of transplantation. She discusses the critical role of early detection, how decompensated cirrhosis impacts survival rates, and the growing trend of earlier liver transplants across the nation. Janet also explores how alcohol use disorder (AUD) and metabolic-associated steatotic liver disease (MASLD) are shaping transplant needs, along with groundbreaking efforts to incorporate AUD treatment into hepatology clinics. With MASLD (formerly known as NAFLD) now being the fastest-growing cause of cirrhosis and liver transplantation, she emphasizes the importance of weight loss as a key strategy for disease management. Research shows that a 7% weight loss can significantly improve liver health by mobilizing fat out of the liver and reducing disease progression. Additionally, she highlights why identifying a surrogate decision-maker is crucial for patients with advanced cirrhosis. Once a patient experiences their first decompensated episode, the average life expectancy is less than two years, and some complications can impair decision-making. Having a surrogate involved early ensures that medical choices align with the patient’s values and preferences. For more expert insights on liver disease and transplantation, subscribe now and visit the Gastroenterology & Hepatology Advanced Practice Provider (GHAPP) website or download the GHAPP app on iOS and Android. Stay informed, stay empowered, and improve patient care.

    4min

  2. HÁ 2 DIAS

    KOL: How Can Healthcare Professionals Improve Patient Outcomes in Those with Cirrhosis?

    Cirrhosis is a progressive liver disease that requires early detection, effective management, and patient education to improve outcomes. In this video, Allison Moser, NP, a Transplant Hepatology Nurse Practitioner at Rush University Medical Center, shares key strategies for healthcare professionals to enhance patient care. She discusses the importance of early screenings for high-risk individuals, including those with a history of alcohol use, metabolic syndrome, and viral hepatitis. By utilizing blood tests, imaging, and elastography, providers can detect cirrhosis early and intervene before complications arise. Managing the root cause—whether through antivirals, alcohol cessation, or lifestyle modifications—is critical to slowing disease progression. As cirrhosis advances, patients may develop ascites, esophageal varices, and hepatic encephalopathy. Allison explains how medications like diuretics, beta-blockers, lactulose, and rifaximin help manage these complications and reduce hospitalizations. For patients with end-stage liver disease, early referral for liver transplant evaluation using MELD score assessments can be life-saving. Beyond medical treatment, patient education and mental health support play a crucial role. Healthcare professionals must emphasize healthy lifestyle choices, alcohol avoidance, and emotional well-being to empower patients in managing their condition. A multidisciplinary approach, involving hepatologists, dietitians, and mental health specialists, ensures comprehensive patient care. Stay informed on the latest research and treatment options to provide the best possible outcomes for cirrhosis patients. Subscribe for more expert insights and visit the Gastroenterology & Hepatology Advanced Practice Provider (GHAPP) website for additional resources. #Cirrhosis #LiverHealth #Hepatology #Transplant #Gastroenterology

    4min

  3. 27 DE FEV.

    Efficacy and Safety of Guselkumab in Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results

    Explore the latest findings on Guselkumab as a maintenance therapy for moderate to severe ulcerative colitis from the Phase 3 QUASAR Maintenance Study. In this Journal Club video module, Shayla Schoenoff, PA-C, reviews key efficacy and safety outcomes in patients who demonstrated a clinical response to Guselkumab IV induction. The randomized, placebo-controlled trial assessed subcutaneous Guselkumab (100 mg every 8 weeks or 200 mg every 4 weeks), showing significant improvements in clinical remission, symptomatic remission, endoscopic response, and steroid-free remission compared to placebo. Additionally, safety outcomes remained consistent across treatment groups, with no new major safety concerns. Watch now to learn how Guselkumab maintenance therapy is shaping treatment options for ulcerative colitis. Visit the GHAPP website or GHAPP ACE app for more educational content.

    6min

  4. 25 DE FEV.

    FAQ: How does the guselkumab data align with the STRIDE II guidelines?

    In this video, Erin Darguzas, NP, from the Inflammatory Bowel Disease Center at Northwestern Medicine, discusses how Guselkumab data aligns with STRIDE II guidelines for monitoring IBD (Inflammatory Bowel Disease) patients over time. Developed by International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) members, STRIDE II provides a treat-to-target framework that outlines short-term, intermediate, and long-term goals for achieving disease control. Erin explains how Guselkumab's clinical trials align with these treatment targets. In induction studies, patients were evaluated at Baseline and Week 12, with clinical remission as the primary outcome—matching STRIDE II's short-term targets. The results showed symptom improvement and mucosal healing by Week 12, supporting early treatment efficacy. In maintenance trials, clinical responders from the induction phase were randomized into maintenance arms, with Week 44 clinical remission as the primary endpoint. Additional key outcomes included corticosteroid-free remission, sustained clinical response, endoscopic improvement, and mucosal healing—meeting intermediate and long-term STRIDE II targets. By demonstrating both short- and long-term efficacy, Guselkumab shows potential for long-term IBD management in alignment with STRIDE II treatment goals. For more expert insights on IBD treatment strategies, visit the Gastroenterology & Hepatology Advanced Practice Provider (GHAPP) website.

    3min

  5. 20 DE FEV.

    Medication Review: What are guselkumab's other FDA indications and how might that affect patient care?

    In this video, Anne Feldman, NP, from Cleveland Clinic, discusses Guselkumab (Tremfya), an FDA-approved treatment for adults with moderate to severe ulcerative colitis, plaque psoriasis, and psoriatic arthritis. With promising Phase 3 clinical trial results, Guselkumab is expected to receive FDA approval for Crohn’s disease, making it a potential first-line advanced therapy or an option for patients who have failed other advanced treatments. Beyond gut-related inflammation, extraintestinal manifestations (EIMs)—affecting the skin, joints, and eyes—are common in IBD (Inflammatory Bowel Disease), especially Crohn’s disease. Up to 40% of IBD patients experience EIMs, sometimes even before their IBD diagnosis. Because Guselkumab is already FDA-approved for psoriasis and psoriatic arthritis, it offers a multisystem treatment approach, addressing both IBD and associated autoimmune conditions. By targeting multiple inflammatory pathways, this therapy has the potential to reduce disease burden and significantly improve quality of life. For more information on IBD treatment strategies and Guselkumab’s role in patient care, visit the Gastroenterology & Hepatology Advanced Practice Provider (GHAPP) website or download the GHAPP ACE mobile app.

    3min

  6. 19 DE FEV.

    KOL Interview: Can You Discuss Any Recent Breakthroughs in the Management of Cirrhosis?

    In this video, Sherona Bau, NP, at Pfleger Institute at UCLA, shares the latest advancements in cirrhosis management, including newly FDA-approved medications and updated AASLD (American Association for the Study of Liver Diseases) guidelines. While there are still limited medications specifically for cirrhosis, recent developments provide promising options for patients with liver disease. One key update is in the management of portal hypertension, where AASLD now recommends non-selective beta blockers like carvedilol for variceal bleeding prophylaxis, particularly due to its vasodilatory effects. Patients with medium or large varices are advised to take these medications to reduce bleeding risks. Another significant procedure being emphasized is the TIPS (Transjugular Intrahepatic Portosystemic Shunt), which is considered for patients with recurrent variceal bleeding or refractory ascites. However, it is generally preferred for those already on a liver transplant list, as there is a small risk of liver failure. There have also been notable advancements in treating Primary Biliary Cholangitis (PBC) with two newly FDA-approved medications: Ivarix (approved June 10) and Cadazopa (approved August 14). While these treatments are not approved for decompensated cirrhosis, they are safe for Child-Pugh Class A patients, though providers are advised to discontinue treatment if the disease progresses to Child-Pugh Class B or C. Additionally, for patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH), the FDA recently approved Rivumet on April 9, marking the first-ever FDA-approved therapy for MASH with liver fibrosis (F2-F3). Although it is not yet approved for cirrhotic patients, further data is expected soon. As liver disease management continues to evolve, staying informed on new treatments and best practices is crucial for improving patient outcomes. For more details, visit the GHAPP website and subscribe for expert insights on liver disease care!

    3min

  7. 18 DE FEV.

    Journal Club: Guselkumab as Maintenance Therapy for Ulcerative Colitis- Phase 3 QUASAR Study Results

    In this video, Shayla Schoenoff, PA-C, reviews the Phase 3 QUASAR maintenance study, evaluating the efficacy and safety of Guselkumab as a maintenance therapy for moderately to severely active ulcerative colitis. This randomized, double-blind, placebo-controlled study assessed patients who previously had an inadequate response to conventional or advanced therapies and demonstrated a clinical response to GUS IV induction therapy. Key findings show that GUS subcutaneous maintenance therapy significantly improved clinical remission rates, symptomatic remission, endoscopic improvement, and steroid-free remission at Week 44 compared to placebo. Patients receiving 100 mg GUS every 8 weeks and 200 mg GUS every 4 weeks showed higher remission rates, with 50% of patients in the 200 mg group achieving clinical remission, compared to 18.9% in the placebo group. Additionally, 69% of GUS-treated patients in clinical remission also achieved endoscopic remission, reinforcing its effectiveness in managing ulcerative colitis. The study also evaluated safety outcomes, showing that the proportion of patients experiencing adverse events was similar across treatment groups. The most common adverse events included COVID-19, ulcerative colitis flare-ups, and arthralgia, with no cases of death, active tuberculosis, anaphylaxis, or serious hepatic adverse events reported. This comprehensive review provides essential insights into GUS maintenance therapy, highlighting its role in long-term ulcerative colitis management. Watch now for a detailed breakdown of the study results, and don’t forget to subscribe for more updates on IBD treatments and clinical trials. Visit the GHAPP website or download the GHAPP ACE app for more information and educational content.

    6min

  8. 17 DE FEV.

    FAQ: What should patients know about living with cirrhosis?

    In this video, Janet Gripshover, CRNP, Nurse Manager at Cedars-Sinai Liver Transplant Program, discusses essential steps for managing cirrhosis to improve quality of life and longevity. The most critical action for anyone living with liver disease is to completely eliminate alcohol consumption, as alcohol accelerates liver damage, increases fibrosis, and raises the risk of decompensated cirrhosis, which can severely impact daily functioning and overall health. A low-sodium, high-protein diet is also vital for cirrhosis management. Reducing sodium intake helps prevent fluid retention, which can cause discomfort, swelling, and difficulty breathing. Adequate protein intake—about 1.2 grams per kilogram of body weight—is crucial to prevent muscle loss often associated with cirrhosis. Since the body struggles to absorb protein efficiently, maintaining proper nutrition and engaging in strength training can help preserve lean muscle mass and overall strength. Regular exercise and staying active play a crucial role in supporting liver function and overall health. Additionally, individuals with cirrhosis should ensure they are up to date on preventive health screenings, including mammograms, prostate exams, and colonoscopies, especially if a liver transplant is a future consideration. Watch this video to learn more about cirrhosis management and practical steps to enhance your health. For additional resources, visit the GHAPP website or download the GHAPP ACE app on iOS and Android. #Cirrhosis #LiverHealth #LiverDisease #CirrhosisManagement #TransplantCare #Hepatology #LiverTransplant #HealthyLiving #LowSodiumDiet #HighProteinDiet #PreventiveCare

    4min
Ver tudo (67)

Sobre

This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs). Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).

Informações

  • Criado por
    Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
  • Anos de atividade
    2023 - 2025
  • Episódios
    67
  • Classificação
    Livre
  • Copyright
    © 2025 GHAPPcast
  • Site do podcast
    GHAPPcast

Você também pode gostar de

Para ouvir episódios explícitos, inicie sessão.

Fique por dentro deste podcast

Inicie sessão ou crie uma conta para seguir podcasts, salvar episódios e receber as atualizações mais recentes.
Selecionar um país ou região

África, Oriente Médio e Índia

Ásia‑Pacífico

Europa

América Latina e Caribe

Estados Unidos e Canadá